DMTK Stock Price, Chart, Stats & News

DermTech, Inc.
Save
3.29M
Market cap
–
Current P/E
–
Forward P/E
DMTK chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 1.80% |
Operating margin | -678.21% |
Pretax margin | -659.57% |
Net margin | -659.57% |
Effective tax rate | – |
ROA | -82.74% |
ROE | -106.46% |
D/E | 0.95x |
Interest coverage ratio | – |
DMTK valuation
P/E | – |
P/S | 0.21x |
P/B | 0.05x |
P/CF | -0.04x |
P/FCF | -0.04x |
P/OCF | -0.04x |
PEG | -0.00x |
EV multiple | 0.15x |
About
DermTech, Inc., a molecular diagnostics firm headquartered in La Jolla, California, specializes in creating and bringing to market advanced, non-invasive genomic tests. Operating within the United States, their innovative solutions facilitate the diagnosis of various dermatological issues, including skin cancer, inflammatory conditions, and age-related skin concerns. A cornerstone of their offerings is the DermTech Melanoma Test (DMT), a sophisticated gene expression analysis.
Similar securities
Based on sector and market capitalization
Report issue










